The Univ of Toronto-hosted Centre for the Commercialization of Regenerative Medicine (CCRM) has struck a licensing deal with the UniQuest, the commercialization arm of Brisbane AU-based Univ of Queensland (UQ) to commercialize a treatment for chemotherapy-induced neutropenia. The treatment, developed by researchers at UQ’s Australian Institute for Bioengineering and Nanotechnology, provides a therapeutic dose of white blood cells from to patients immediately after chemotherapy. The white blood cells are extracted from umbilical cord blood to produce a transfusion-ready dose to administer to patients. A member of the UQ research team — Dr Nick Timmins — is now based at CCRM, which is a leader in commercializing regenerative medicine technologies and cell and gene therapies….